Critical Survey: Coya Therapeutics (NASDAQ:COYA) and Molecular Templates (NASDAQ:MTEM)

Coya Therapeutics (NASDAQ:COYA) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Coya Therapeutics and Molecular Templates’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	N/A	-35.63%	-30.96%
Molecular Templates	-61.35%	-260.50%	-46.90%

Valuation and Earnings

This table compares Coya Therapeutics and Molecular Templates”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$9.55 million	10.79	-$7.99 million	($0.85)	-8.29
Molecular Templates	$57.31 million	0.17	-$8.12 million	($2.70)	-0.54

Coya Therapeutics has higher earnings, but lower revenue than Molecular Templates. Coya Therapeutics is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Coya Therapeutics and Molecular Templates, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	0	0	3	0	3.00
Molecular Templates	0	0	0	0	N/A

Coya Therapeutics presently has a consensus price target of $16.67, suggesting a potential upside of 136.41%. Given Coya Therapeutics’ higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Molecular Templates.

Risk & Volatility

Coya Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 13.6% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics beats Molecular Templates on 8 of the 12 factors compared between the two stocks.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

About Molecular Templates

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.